All news

Argus upgrades Elevance Health to Buy with $510 target

Alpha Vantage · Benzinga · · AI-summarised by FinFlash

Argus Research analyst David Toung upgraded Elevance Health to Buy with a $510 price target, one of five analyst upgrades on the day. The consensus target sits at $482.38 versus a $433.93 share price, implying roughly 11.2% upside, with ratings at 15 Buy, 7 Hold and 0 Sell. The upgrade signals renewed analyst confidence in the managed-care name.

Read original source

ELV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.